The Ministry of Health, Labor and Welfare (MHLW) on December 18 presented a proposal to define the scope of products…
HOME > TOP STORIES
TOP STORIES
-
ORGANIZATION JPWA Sets Up New Committee on Consumption Tax, NHI Drug Pricing Issues
July 12, 2013
-
BUSINESS Drug Makers to Disclose Payment Information This Summer Based on Transparency Guidelines
July 11, 2013
-
BUSINESS Blood Derivative Titan CSL Set to Beef Up Japan Biz with New Products
July 10, 2013
-
REGULATORY TPP Member States to Brief Japan on Drug Pricing, Intellectual Property on July 25
July 9, 2013
-
ORGANIZATION JSGM Officially Announces Unified Brand Name Plan for Generic Combination Drugs; 1st Single Name to Be Given to Preminent
July 8, 2013
-
ORGANIZATION JSGM Working to Build Consensus on Unified Brand Names for Generic Combination Drugs
July 5, 2013
-
ACADEMIA “No Data Manipulation” in VART Study of Diovan: Interim Report of Japanese Society of Hypertension
July 4, 2013
-
REGULATORY Notification Calls for Simultaneous Filing of Applications for Companion Diagnostics and Drugs
July 3, 2013
-
BUSINESS Japanese Society of Chemotherapy Joins Hands with Pharmas, Govt to Spur New Antibiotic Development
July 2, 2013
-
ORGANIZATION JMA Sets Up Pharmaceutical Affairs Section
July 1, 2013
-
BUSINESS Bayer Yakuhin to Shift Resources to Innovative New Drugs: President Brunn
June 28, 2013
-
ACADEMIA NHO Attains 30% Volume-Based Generic Target in FY2012
June 28, 2013
-
REGULATORY MHLW Maps Out New Vision for Pharma Industry; Research-Based Makers Will See “Survival of the Fittest,” It Says
June 27, 2013
-
BUSINESS Eisai to Suspend Sales of Future Mainstay Antiepileptic Drug in Germany
June 26, 2013
-
BUSINESS Filgrastim Biosimilars: Overseas Track Record vs. “Purely Made-in-Japan” Label
June 25, 2013
-
ACADEMIA Makers Should Venture into Drug Development Using iPS, CiRA Adviser Asonuma Says
June 25, 2013
-
REGULATORY FPMAJ May Find it Difficult to Compile Unified Statement of Views on TPP Talks Due to Disagreement among Original and Generic Drug Makers
June 24, 2013
-
ORGANIZATION JGA Concerned about TPP Talks, Hopes Japan Will Adopt US Rules Favorable to Generic Makers
June 24, 2013
-
ORGANIZATION JPMA Weighs Scheme to Allow Use of Clinical Research Evidence for Drug Applications
June 21, 2013
-
BUSINESS Anatomy of Mutual Reliance - Diovan Papers and Company Part 2: Explanations to the World Urged
June 21, 2013
ページ
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
Will an “off-year” drug price revision happen in April 2025 or not? Over the last week, expectations have been up…
For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…